Oncologist frets about premature decisions based on PET/CT
"We need to be very rigorous about all aspects of imaging: the way FDG-PET is acquired, its analysis, and the structure of the clinical trial in which it is imbedded.
"We need to be very rigorous about all aspects of imaging: the way FDG-PET is acquired, its analysis, and the structure of the clinical trial in which it is imbedded.
"A concern we have in the treatment community is that physicians are already making decisions based on early PET assessments when we are still not clear about the optimal timing, the interpretation, and whether changing therapy (on the basis of imaging findings) affords a benefit over continuing the prior therapy.
"It is really critical not to ask too many questions in these clinical trials. We should take it one step at a time."
-Dr. Sandra Horning, a professor of medicine (oncology) at Stanford University and president of the American Society of Clinical Oncology, speaking at the 2006 Academy of Molecular Imaging meeting in Orlando.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
